Market news

FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.

Fresenius Medical Care updates China strategy, and incurs a 110 million euro charge while focusing on advanced dialysis tech.

Fresenius Medical Care (FMS) said Friday it has refined its China commercial strategy, with plans to

The U.S. Food and Drug Administration (FDA) on Tuesday issued a warning letter to Fresenius Medical Care AG & Co. KGaA’s Fresenius USA Manufacturing following a March 2026 inspection at its Ogden, Utah production facility. In a letter to the...

Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.

Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.

U.S. referral execution gap offset by strong margin expansion and transformation savings.

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

Fresenius Medical Care is expanding its BEACON-US clinical initiative to build real-world evidence for high-volume hemodiafiltration therapy in the U.S. The program evaluates the 5008X CAREsystem and HVHDF across large patient populations, with data indicating fewer hospitalizations and improved survival outcomes. These findings point to potential gains in patient care quality and healthcare system efficiency as the therapy is more widely adopted. For investors tracking XTRA:FME, the...

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer of the Care Delivery segment, reshaping leadership oversight of its global clinic operations. See our latest analysis for Fresenius Medical Care. The leadership change at Fresenius Medical Care comes just after a Q2 report where solid operating income and organic growth were followed by a sharp 1 day share price decline of...

Moby summary of Fresenius Medical Care AG & Co. KGaA's Q2 2026 earnings call

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

FMS delivers 23% operating income growth and margin expansion, while navigating US referral headwinds and TDAPA roll-off.

Fresenius Medical Care (NYSE:FMS) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and

Fresenius Medical Care (NYSE:FMS) shares fell 8. 0% to €41.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in t

Fresenius Medical Care (FMS) reported Q2 adjusted earnings late Monday of 1.13 euro ($1.30) per shar

BAD HOMBURG, Germany, Aug. 3, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, has appointed Cassie McLean (48) as a member of the M...

Tipranks Press Release.

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

German health care group Fresenius on Monday reaffirmed its annual earnings outlook, maintaining its forecast for adjusted earnings growth this year. Excluding its stakes in Fresenius Medical Care and Vitrea, the company continues to expect core earnings per share to grow by 5% to 10% in fiscal 2026.

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.